AUG 13, 2019 8:02 AM PDT

Novel Drug Target for Dilating Microvessels

WRITTEN BY: Nouran Amin

Medical scientists at Augusta University have discovered a natural occurring chemical that dilates blood vessels dilate as well as signaling larger blood vessels that more blood is needed. Their studies were particularly helpful in diastolic heart failure which is a characterized by the inability of the left ventricle to relax and fill blood adequately. the natural inhibitor of that chemical goes up and communication with upstream blood vessels goes down. And, when they bring the inhibitor down, it reduces the heart dysfunction, they report in the journal Circulation: Heart Failure.

Learn more on how our hearts pump blood:

"What we are talking about here even many cardiologists cannot see," says Dr. Zsolt Bagi from Augusta University’s Department of Physiology who was refereeing to the microvasculature of the heart muscle.

Although when we think of heart failure—thoughts of high cholesterol, high blood pressure, and smoking start to surface. However, heart failure can also arise from microvascular dysfunction.

In the study, published in the journal Circulation: Heart Failure, researchers found that the chemical adenosine—known to facilitate dilation—will not function effectively if levels if its inhibitory compound, adenosine kinase, are increased.

“In a healthy state, the two provide balance for each other, but adenosine levels are typically somewhat higher. If you are healthy, when a portion of your heart needs more blood and oxygen for that walk or to hike up some stairs, adenosine levels go up and adenosine kinase levels decrease, which is good,” says MD/PhD student Alec Davila.

“Now they've shown that in their animal model of disease, giving a drug that blocks adenosine kinase boosts the intrinsic adenosine production back where we need it, which is also good,” says Bagi.

Researchers have found that adding the adenosine kinase inhibitor has improved the dilation of blood vessels in both animal and human microvessels.

"The novelty here is that adenosine really amplifies the signal," says Bagi. “The adenosine kinase inhibitor they used appears to be pretty specific, and is being looked at as well for epilepsy, where levels of adenosine kinase also are high.”

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 05, 2021
Drug Discovery & Development
Personalized Treatment for Sickle Cell Disease
MAR 05, 2021
Personalized Treatment for Sickle Cell Disease
Globally, the most prevalent inherited blood disease is sickle cell which affects 70,000 to 100,000 Americans. Despite s ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
MAY 02, 2021
Cannabis Sciences
Medical Cannabis for Epilepsy May Be Linked to Early Puberty
MAY 02, 2021
Medical Cannabis for Epilepsy May Be Linked to Early Puberty
Current research suggests that cannabidiol (CBD) oil may be effective in managing seizures in childhood-onset epilepsy. ...
MAY 15, 2021
Drug Discovery & Development
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
MAY 15, 2021
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
According to the World Health Organization (WHO), in 2016, around 2 billion adults around the world were overweight ...
MAY 22, 2021
Drug Discovery & Development
FDA Approves Trials for Ketamine to Treat Parkinson's
MAY 22, 2021
FDA Approves Trials for Ketamine to Treat Parkinson's
The US FDA has approved PharmaTher’s Investigational New Drug application to begin Phase 2 clinical trials for ket ...
JUN 17, 2021
Drug Discovery & Development
New COVID Drug Reduces Deaths in Patients with no Antibodies
JUN 17, 2021
New COVID Drug Reduces Deaths in Patients with no Antibodies
US drugmaker, Regeneron, in a partnership with Oxford University, has found that its new drug is capable of reducing COV ...
Loading Comments...